Page 138 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $1.62
52wk Low $0.35 Ocugen, Inc. OCGN $0.39
263 Great Valley Parkway
Malvern, PA 19355

(USD - in millions) www.ocugen.com
Market Cap 105.1
Enterprise 58.1
Basic Shares Out. 256.50 COMPANY OVERVIEW
Float 252.81
Institutional Holdings 12.89% Detailed Analysis:Channelchek.com
Short Interest 24.69
Avg. 90-Day Volume 1.83 Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through courageous
EPS Data innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene therapy
2021 2022 2023 platform has the potential to treat multiple retinal diseases with a single
CQ1 (0.04) (0.09) (0.07) product, and we are advancing research in infectious diseases to
CQ2 (0.13) (0.09) (0.10) support public health and orthopedic diseases to address unmet
medical needs.
CQ3 (0.05) (0.10) (0.06)
CQ4 (0.07) (0.10) (0.06)
CY (0.30) (0.38) (0.28) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.23
ROE (ttm) -98.28
Debt-to-Total Cap. (mrq) 9.98
Fiscal Year End 31-Dec

263 Great Val Malvern PA 19355

Key Executives
CEO: Musunuri, Shankar
CFO: Breininger, Michael
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures